Who Owns Namenda?
Namenda is a brand of memantine owned in the United States by AbbVie Inc. (NYSE: ABBV), which acquired it through the 2020 Allergan merger. Memantine was originally developed by Merz Pharma of Germany and licensed to Forest Laboratories for the US market. The FDA approved Namenda in 2003 for moderate to severe Alzheimer's disease. Patents expired in 2015 and memantine is widely generic.
Namenda Timeline
United StatesOfficial Website
Who Owns Namenda?
- Parent Company: AbbVie Inc.
- Ownership Type: Acquired
- Acquisition Year: 2020
- Company Type: Publicly Traded
- Stock Ticker: NYSE: ABBV
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Namenda | AbbVie Inc. | Acquired |
Where to Buy
Disclosure: We may earn commission from purchases
Namenda on AmazonAdvertisement
History of Namenda
- Founded: 2003
- Founders: Merz Pharma internal development
- Acquired by AbbVie Inc.: 2020
Merz Pharma, a family-owned German pharmaceutical company, developed memantine, an NMDA receptor antagonist, for Alzheimer's disease through the 1990s. The drug had earlier been studied for other neurological uses in Germany under the name Axura.
Merz licensed US rights to Forest Laboratories, which won FDA approval for Namenda in October 2003 for moderate to severe Alzheimer's disease. It was the first drug approved in the US for that severity level, filling a gap where cholinesterase inhibitors were indicated mainly for milder disease. It launched internationally as Ebixa through Merz's partner Lundbeck in Europe.
Namenda grew into a blockbuster, reaching over $1.5 billion in annual sales by the early 2010s. Actavis acquired Forest in 2014 for $25 billion, inherited the brand, and rebranded as Allergan the following year.
Controversy came in 2014 when Forest attempted to discontinue immediate-release Namenda to force patients onto the patent-extended Namenda XR before generic entry. New York's attorney general sued, and a federal injunction blocked the withdrawal, another landmark pharmaceutical product hopping case.
Advertisement
Generic memantine launched in July 2015, collapsing branded sales. AbbVie's 2020 acquisition of Allergan transferred the brand to its current owner, where it sits as a legacy product in the neuroscience portfolio.
About AbbVie Inc.
What does AbbVie own?
AbbVie owns a portfolio of prescription drug brands including Skyrizi, Rinvoq, Humira, Imbruvica, Venclexta, Vraylar, Ubrelvy, Qulipta, and Elahere, plus the aesthetics products Botox Cosmetic and Juvederm acquired through the 2020 Allergan deal. All are internally held product brands rather than separate subsidiaries.
Is AbbVie publicly traded?
Yes. AbbVie trades on the New York Stock Exchange under ticker ABBV and is a component of the S&P 500. It has traded publicly since its January 2013 spin-off from Abbott Laboratories, and Abbott retains no ownership stake.
Who founded AbbVie?
AbbVie was not founded by individuals but created as a corporate spin-off from Abbott Laboratories in 2013, led at launch by CEO Richard A. Gonzalez. Its operating heritage traces to Dr. Wallace C. Abbott, who founded Abbott's predecessor drug company in Chicago in 1888.
Advertisement
Where is AbbVie headquartered?
AbbVie is headquartered in North Chicago, Illinois, in the same suburban Chicago corridor where Abbott has long been based. Its principal offices sit at 1 North Waukegan Road.
How many brands does AbbVie own?
AbbVie markets roughly a dozen major product brands, led by Skyrizi, Rinvoq, Humira, Botox, Juvederm, Imbruvica, and Venclexta, plus smaller products across eye care and neuroscience. Unlike consumer conglomerates, its brands are individual prescription medicines rather than retail labels.
Who owns AbbVie?
AbbVie is owned by public shareholders, with Vanguard, BlackRock, and State Street as the largest institutional holders. Robert A. Michael serves as chairman and chief executive officer. No founding family or single shareholder controls the company.
What happened to Humira?
U.S. biosimilar competitors launched in January 2023 after AbbVie's patent settlements allowed entry. Humira worldwide revenue fell from a $21.2 billion peak in 2022 to $4.54 billion in 2025, while Skyrizi and Rinvoq grew to replace it, pushing total company revenue to a record $61.16 billion.
Advertisement
- Founded: 2013
- Headquarters: North Chicago, Illinois, USA
- Company Type: Publicly Traded
- Stock: NYSE: ABBV
- Revenue: $61.16 billion (FY2025)
- Employees: Approximately 55,000
Where Is Namenda Made / Based?
- Headquarters: North Chicago, Illinois, USA
Namenda Categories & Tags
Namenda Recalls & Controversies
The defining controversy is the 2014-2015 product hopping litigation, in which Forest and Actavis attempted to pull immediate-release Namenda to push patients to the extended-release version ahead of generic competition. A federal court granted a preliminary injunction forcing continued sale of the original formulation, establishing a precedent on forced product switching.
Standard NMDA antagonist safety labeling applies. No major product recalls are on record.
Brands Owned by AbbVie Inc.
Advertisement
Namenda Ownership: Pros & Cons
Advantages
- +Held by a large-cap pharma with stable distribution
- +First-approved moderate-to-severe Alzheimer's agent
- +Established two-decade safety record
Considerations
- -Generic competition eliminated most branded revenue
- -Product hopping litigation history attached to the brand
- -Minor asset within AbbVie's priorities
- -Class faces clinical relevance questions alongside newer therapies
Frequently Asked Questions About Namenda
Advertisement
Sources & Further Reading
Competitors to Namenda
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Eisai | Japan | 1996 | Mass market | Global | All Genders | |
| Novartis | Switzerland | 1997 | Mass market | Global | All Genders | |
| Eli Lilly | USA | 2024 | Mass market | Global | All Genders | |
| Johnson Johnson | USA | 2001 | Mass market | Global | All Genders | |
| Pfizer | USA | 2020 | Mass market | United states | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsAricept
Owned by Eisai
Brand name for donepezil, the most prescribed Alzheimer's disease cholinesterase inhibitor, developed by Eisai and formerly co-marketed with Pfizer.
neurologyalzheimersdementia
Healthcare PharmaceuticalsExelon
Owned by Novartis
Brand name for rivastigmine, a prescription cholinesterase inhibitor developed by Novartis for treating mild-to-severe Alzheimer's disease and Parkinson's disease dementia. Available as capsules, oral solution, and transdermal patch.
neurologyalzheimersdementia
Healthcare PharmaceuticalsKisunla
Owned by Eli Lilly and Company
Eli Lilly's donanemab, an anti-amyloid antibody for early Alzheimer's disease approved by the FDA in 2024, competing directly with Eisai and Biogen's Leqembi.
neurologyalzheimersdementia
Healthcare PharmaceuticalsRazadyne
Owned by Johnson & Johnson
Brand name for galantamine, a cholinesterase inhibitor for Alzheimer's disease developed by Janssen and sold in the US by Johnson & Johnson's Janssen division.
neurologyalzheimersdementia
Healthcare PharmaceuticalsNurtec ODT
Owned by Pfizer Inc.
CGRP antagonist (rimegepant) for acute and preventive migraine treatment, acquired by Pfizer through the 2022 Biohaven acquisition for approximately $11.6 billion.
migrainecgrp-inhibitorneurology
Competitive Analysis
Market Positioning: Namenda competes with 5 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Namenda
Looking for brands with different ownership structures? These similar brands are not owned by AbbVie Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsAvaility
Owned by Availity
The largest real-time health information network in the US, owned by a consortium of major health insurers and Novo Holdings.
healthcare-technologyclearinghouseclaims-processing
Privately Owned
Availity is privately owned, unlike Namenda which is under a publicly traded parent company.
Healthcare PharmaceuticalsBand-Aid
Owned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
wound-careadhesive-bandagefirst-aid
Privately Owned
Band-Aid is privately owned, unlike Namenda which is under a publicly traded parent company.
Healthcare PharmaceuticalsBenadryl
Owned by Kenvue
American brand of antihistamine medication used to treat allergies, itching, and cold symptoms, manufactured and marketed by Johnson & Johnson.
antihistamineallergy-reliefcold-medicine
Privately Owned
Benadryl is privately owned, unlike Namenda which is under a publicly traded parent company.
Healthcare PharmaceuticalsBoehringer Ingelheim
Owned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
pharmaceuticalsprescription-drugsanimal-health
Privately Owned
Boehringer Ingelheim is privately owned, unlike Namenda which is under a publicly traded parent company.
Healthcare PharmaceuticalsBoots
Owned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
pharmacyhealth-beautyuk-retail
Privately Owned
Boots is privately owned, unlike Namenda which is under a publicly traded parent company.
Healthcare PharmaceuticalsBrainlab
Owned by Brainlab SE
Munich surgical navigation and radiotherapy software brand installed in about 4,000 hospitals worldwide.
medical-technologysurgical-navigationradiosurgery
Privately Owned
Brainlab is privately owned, unlike Namenda which is under a publicly traded parent company.
AbbVie Inc. Stock Information
Advertisement
Jobs at AbbVie Inc.
Latest News About Namenda
Advertisement
Related Articles About Namenda
View more articles
Health
The Pharmaceutical Giants Behind Common Medicines
Eli Lilly is now #1 pharma ($65.2B, Mounjaro + Zepbound). Novo Nordisk has 59.6% GLP-1 share. Merck's Keytruda is $31.7B. Pfizer faces a $20B patent cliff. Discover who makes your medicines. Explore our database.
Who Brands StaffNov 6, 2026
PharmaceuticalsEli LillyNovo Nordisk
News & Updates
Monthly IPO Roundup: October 2026 -- September's Biggest Listings
September 2026 IPOs: Shein raised $1.7B in Hong Kong's largest listing of the year and closed flat, NSE India debuted at a $46B valuation in the country's second-largest IPO, Enflame surged 179% in Shanghai, and Anthropic's $2 trillion S-1 surfaced. Full recap.
Who Brands StaffOct 1, 2026
Ipo RoundupIpoStock Market
Health
Dental Brand Ownership Beyond Colgate and Crest
Colgate holds 41.3% global toothpaste share. P&G (Crest, Oral-B) has 14.1%. Haleon (Sensodyne) has 4.4%. Church & Dwight is the only independent at scale. The oral care market is $47.2B. Explore our database.
Who Brands StaffNov 12, 2026
ColgateCrestOral B
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization